Papua New Guinea vs Western Pacific (WHO region): Previously treated cases tested for RR-/MDR-TB
Papua New Guinea
100.0%
in 2024
Western Pacific (WHO region)
86.0%
in 2024
Papua New Guinea rank
1st
Western Pacific (WHO region) rank
3rd
Previously treated cases tested for RR-/MDR-TB over time
- Papua New Guinea
- Western Pacific (WHO region)
How they compare
Papua New Guinea currently reports 100.0% against 86.0% in Western Pacific (WHO region), a difference of 14.0%.
That makes Papua New Guinea's figure about 1.2 times Western Pacific (WHO region)'s.
The two have swapped places 1 time across 5 shared years of data; in 2015 it was Western Pacific (WHO region) ahead.
Papua New Guinea ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
Across the 2 decades both report, Papua New Guinea averaged higher in 1 and Western Pacific (WHO region) in 1.
Head to head by decade
| Decade | Papua New Guinea | Western Pacific (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 43.3% | 80.0% | 36.7% | Western Pacific (WHO region) |
| 2020s | 100.0% | 90.0% | 10.0% | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Papua New Guinea or Western Pacific (WHO region)?
- Papua New Guinea, at 100.0% against 86.0% in Western Pacific (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Papua New Guinea and Western Pacific (WHO region)?
- 14.0%, with Papua New Guinea ahead.
- How many years of comparable data are there for Papua New Guinea and Western Pacific (WHO region)?
- 5 years are reported by both, from 2015 to 2024.
- How do Papua New Guinea and Western Pacific (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Papua New Guinea ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.